- May 2024 Letter to Shareholders
- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn Announces Webcast to Provide Company Update
- CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
- November 2023 Letter to Shareholders
- CytoDyn Announces Company Updates and Investment Community Update Webcast
More ▼
Key statistics
On Thursday, Cytodyn Inc (296:STU) closed at 0.202, 62.90% above the 52 week low of 0.124 set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.218 |
---|---|
High | 0.2540 |
Low | 0.202 |
Bid | 0.20 |
Offer | 0.222 |
Previous close | 0.21 |
Average volume | 26.09k |
---|---|
Shares outstanding | 993.37m |
Free float | 985.39m |
P/E (TTM) | -- |
Market cap | 234.93m USD |
EPS (TTM) | -0.055 USD |
Data delayed at least 15 minutes, as of May 23 2024.
More ▼